I am a former Bain Consultant with significant experience in strategic planning and portfolio analysis for Life Sciences companies and Life Sciences investors. Having begun my career at Eli Lilly evaluating pipeline assets and supporting portfolio optimization, forecasting, and business unit strategic planning, I bring a deep knowledge of the Life Sciences space.
I also worked as a consultant with Leerink Swann focused on the Life Sciences space with an emphasis on assessing and valuing technologies and assets for Life Sciences companies and investors. I began working as an independent life-science consultancy 8 years ago emphasizing portfolio planning and due-diligence for life-science companies and life-science investors.
My recent independent consulting work has been focused on due diligence and supporting emerging Life Sciences companies with strategic consulting, primarily focused on growth optimization. These cover the gamut of disease states and span drugs, medical devices, and diagnostics.
Umbrex independent consultants are available where you need them – in all major markets and every global region.
